This observational study seeks to describe the outcomes for individuals who choose to receive integrative oncology care. We will report on clinical outcomes of our patients in terms of whether cancer comes back after treatment (recurrence rates) and survival. We are also interested in identifying therapies recommended to our patients and length of hospice stay when applicable. You will not directly benefit from the study, but information gathered during the course of this study may help us begin to assess the longer-term effects of integrative naturopathic, traditional, Chinese and palliative medicine on cancer patients. To read more about this study, please click on the study title above.
PURPOSE: This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrative Oncology (IO) and their effects on breast cancer patients in community settings.
This study is ongoing but not recruiting new participants.
Founded in 2009, BIORC evaluated the effectiveness of integrative oncology care in our cancer patients. It has now merged with the BOS study.
The goal of this study is to collect as much data as possible over a five-year period with the hope of finding dietary and lifestyle factors associated with a slower disease progression. To participate in or read more about this study, please click on the study title above.
The goal of this PD study is to collect as much data as possible over a five-year period with the hope of finding dietary and lifestyle factors associated with a slower disease progression.
To participate in or read more about this study click on the study title above.
This is a Phase II study seeking to determine whether administration of different doses of glutathione or placebo, as a nasal spray, improves Parkinson’s disease (PD) symptoms over time in a population of individuals with PD.
This case-control study will recruit individuals with a diagnosis of MS and healthy controls. Individuals will be asked to come to Bastyr Clinical Research Center for a single study visit, at which time dietary intake, current medications and supplements, other medical diagnoses, and coagulation will be evaluated.
Parkinson's disease (PD) is considered a progressive and irreversible neurodegenerative disease. Current therapies improve disease symptoms, however none alter the underlying degenerative course. Research suggests the loss of brain glutathione, a powerful antioxidant, is one of the earliest changes to occur in the brain of PD patients and the magnitude of glutathione depletion parallels the severity of PD. This study will look at the use of intranasal glutathione in PD patients to determine safety, tolerability, and the impact on PD symptoms.
A Clinical Trial of Mushroom (PSK) for Treatment of Breast Cancer, The Bastyr University/University of Washington PCCTR Oncomycology Research Center will investigate the immunologic and antitumor effects of Trametes versicolor (Tv) a traditional Chinese medicine medicinal mushroom, for use in the treatment of breast cancer patients in the U.S. This study is not yet recruiting.
This study will evaluate quercitin’s effects on blood glucose and blood vessel function (endothelial function) in patients with type 2 diabetes in comparison to placebo and Acarbose, a pharmaceutical anti-diabetic agent. The study is no longer recruiting and is in data analysis phase.